Literature DB >> 17197543

Transcriptional regulation of IL-8 by Staphylococcus aureus in human conjunctival cells involves activation of AP-1.

Isabella Venza1, Maria Cucinotta, Silvana Caristi, Giuseppe Mancuso, Diana Teti.   

Abstract

PURPOSE: To identify signal transduction pathways involved in interleukin (IL)-8 expression by human conjunctival cells challenged with Staphylococcus aureus.
METHODS: Conjunctival cells were cultured in the presence of live or heat-killed S. aureus. IL-8 protein and mRNA were determined by ELISA and RT-PCR, respectively. Activation of mitogen-activated protein kinases (MAPKs) and NF-kappaB was analyzed by Western blot analysis with phosphospecific antibodies. Conjunctival cells were transfected with wild-type (wt) or mutated IL-8 promoters (IL-8-97, lacking the AP-1 site; IL-8-97 mutant C/EBP; IL-8-97 mutant NF-kappaB; IL-8/AP-1 double mutant for C/EBP and NF-kappaB) or c-Jun-NH(2)-terminal kinase (JNK)-responsive GAL-c-Jun. In further experiments, cells were cotransfected with wt IL-8 promoter and expression plasmids for p38MAPK-responsive C/EBP homologous protein (CHOP) or wt or dominant negative transactivation domain mutant (TAM-67) c-Jun. A protein-DNA binding study was performed by electrophoretic mobility shift assay (EMSA), to identify the transcription factors bound to the IL-8 promoter.
RESULTS: S. aureus induced significant IL-8 expression and synthesis in human conjunctival epithelial cells by activating c-Jun phosphorylation and transactivation potential via JNK. The IL-8 promoter activation was NF-kappaB- and p38MAPK-independent. Transfection and EMSA experiments suggested that only AP-1 transcription factors were necessary for optimal IL-8 expression.
CONCLUSIONS: Human conjunctival epithelial cells possess the ability to respond to Gram-positive S. aureus and to activate the innate immune response by the IL-8 gene expression. These results are the first to delineate the transcription factors involved in S. aureus-induced IL-8 release by conjunctival epithelium.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17197543     DOI: 10.1167/iovs.06-0081

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  5 in total

1.  Insulin modulates the inflammatory granulocyte response to streptococci via phosphatidylinositol 3-kinase.

Authors:  Sybille Kenzel; Miriam Mergen; Julius von Süßkind-Schwendi; Julia Wennekamp; Sachin D Deshmukh; Monika Haeffner; Antigoni Triantafyllopoulou; Sebastian Fuchs; Susan Farmand; Sandra Santos-Sierra; Jochen Seufert; Timo K van den Berg; Taco W Kuijpers; Philipp Henneke
Journal:  J Immunol       Date:  2012-09-26       Impact factor: 5.422

2.  Role of human CD36 in bacterial recognition, phagocytosis, and pathogen-induced JNK-mediated signaling.

Authors:  Irina N Baranova; Roger Kurlander; Alexander V Bocharov; Tatyana G Vishnyakova; Zhigang Chen; Alan T Remaley; Gyorgy Csako; Amy P Patterson; Thomas L Eggerman
Journal:  J Immunol       Date:  2008-11-15       Impact factor: 5.422

3.  Glycogen Synthase Kinase 3α Is the Main Isoform That Regulates the Transcription Factors Nuclear Factor-Kappa B and cAMP Response Element Binding in Bovine Endothelial Cells Infected with Staphylococcus aureus.

Authors:  Octavio Silva-García; Rosa Rico-Mata; María Cristina Maldonado-Pichardo; Alejandro Bravo-Patiño; Juan J Valdez-Alarcón; Jorge Aguirre-González; Víctor M Baizabal-Aguirre
Journal:  Front Immunol       Date:  2018-01-29       Impact factor: 7.561

4.  miR-106a Is Downregulated in Peripheral Blood Mononuclear Cells of Chronic Hepatitis B and Associated with Enhanced Levels of Interleukin-8.

Authors:  Zhongsi Hong; Haiyu Hong; Jian Liu; Xiaobin Zheng; Mingxing Huang; Chunna Li; Jinyu Xia
Journal:  Mediators Inflamm       Date:  2015-07-22       Impact factor: 4.711

5.  CCL20/MIP-3 alpha mRNA expression in the conjunctival epithelium of normal individuals and patients with vernal keratoconjunctivitis.

Authors:  Noriko Inada; Akiko Ishimori; Jun Shoji
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-08-30       Impact factor: 3.117

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.